Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;59(8):1861-1870.
doi: 10.1080/10428194.2017.1403601. Epub 2017 Nov 29.

Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience

Lisa Giulino-Roth  1   2 , Tara O'Donohue  1   2 , Zhengming Chen  3 , Tanya M Trippett  2 , Elizabeth Klein  2 , Nancy A Kernan  2 , Rachel Kobos  2 , Susan E Prockop  2 , Andromachi Scaradavou  2 , Neerav Shukla  2 , Peter G Steinherz  2 , Alison J Moskowitz  4 , Craig H Moskowitz  4 , Farid Boulad  1   2
Affiliations

Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience

Lisa Giulino-Roth et al. Leuk Lymphoma. 2018 Aug.

Abstract

To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated with autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With a median follow-up of 9.6 years, the 10-year overall survival (OS) and event-free survival (EFS) were 74.1 and 67.1% respectively. Absence of B-symptoms, chemotherapy-sensitive disease, and transplant date after 1997 were each associated with superior EFS [HR 0.12 (p = .0015), 0.18 (p = .0039), and 0.17 (p = .0208), respectively]. Childhood Hodgkin International Prognostic Score at relapse (R-CHIPS) was calculated in a subset of patients (n = 22) and a lower score was associated with improved OS (HR 0.29, p = .0352) and a trend toward improved EFS (HR 0.38, p = .0527). In summary, ASCT results in durable remission for the majority of pediatric patients with relapsed HL. R-CHIPS should be evaluated in larger cohorts as a potential predictive tool.

Keywords: Clinical results; lymphoma and Hodgkin disease; marrow and stem cell transplantation; neoplasia; prognostication.

PubMed Disclaimer

Conflict of interest statement

Acknowledgements and Declaration of Interests: The authors have no conflicts of interest to disclose.

Figures

Figure 1:
Figure 1:
Probabilities of event free survival (A) and overall survival (B) for the entire cohort
Figure 2:
Figure 2:
(A-B) Probabilities of event free survival (A) and overall survival (B) for patients with chemotherapy sensitive disease (defined as CR or PR at time of ASCT) compared to chemotherapy resistant disease (defined as SD or PD). (C-D) Probabilities of event free survival (C) and overall survival (D) for patients transplanted in 1989–1997 compared to 1998–2013. (E-F) Probabilities of event free survival (E) and overall survival (F) based on R-CHIPS.
See this image and copyright information in PMC

References

    1. Bradley MB, Cairo MS. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 2008;41:149–158. - PubMed
    1. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994;12:297–305. - PubMed
    1. Hudson MM, Donaldson SS. Treatment of pediatric Hodgkin’s lymphoma. Semin Hematol 1999;36:313–323. - PubMed
    1. Kelly KM, Hodgson D, Appel B, et al. Children’s Oncology Group’s 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 2013;60:972–978. - PubMed
    1. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997;20:21–26. - PubMed

LinkOut - more resources